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LAw, PoLICY, AND MARKET IMPLICATIONS OF
GENETIC PROFILING IN DRUG DEVELOPMENT
Michael J. Malinowski*

INTRODUCTION
Completion of a map of the human genome1 and the explosive
emergence of a multitude of complementary technologies ranging
from DNA chips (commonly referred to as ''biochips")2 to sophisti
cated software have transformed· great expectations for genetic
n1edicine into goals potentially obtainable in the foreseeable future.3
*

1

Emest and Iris Eldred Associate Professor of Law Science, and Public Health, Paul M.
Hebert Law Center, Louisiana State University. This article originated in presentations
made at the University of Arizona College of Pharmacy in February 2001 and at the Loui
siana State University in February 2002. The author would like to thank those who partici
pated in these forums and shared their comments. The author also would like to thank his
students at Hofstra University School of Law during the spring 2002 semester for interac
tions that enriched this article. This article was submitted for publication in April 2002,
and does not necessarily reflect events thereafter.
On June 26, 2000, U.S. government-led and privately funded teams of scientists jointly
announced their completion of a rough map of the human genome. See What's News
WA LL ST. J. EuR., June 27, 2000, available at 2000 WL-WSJE 21064884. See gener
ally 291 SCI. 1145 (February 16, 2001) (issue entitled ''The Human Genome"); 409 NATURE
745 (Feb. 15, 2001) (issue dedicated to the release of a draft map of the human genome).
World-Wide,

See also International Human Genome Sequencing Consortium, Initial Sequencing and Analysis of
the Human Genome, 409 NATURE 860, 872 fig. 9 (Feb. 15, 2001) (draft map of the human
genome); Michael D. Lemonick, The Genome is Mapped. Now What?, TIME, July 3, 2000, at
24-29. Information about the Human Genome Project may be obtained from the Internet
site of the National Human Genome Research Institute (NHGRI), available at www.nhgri.
nih.gov (last visited Mar. 24, 2002).
2

For a discussion of DNA chip technology and how it is accelerating drug development
that is readily accessible to non-scientists, see CYNTHIA ROBBINS-ROTH, FROM ALCHEMY TO
IPO: THE BusiNESS oF BIOTECHNOLOGY 73-78, 225 tbl. 8.1 (Perseus Publishing, 2000).

3

For discussion of the range of enabling technologies being utilized for identification of
genetic expression, see Michael J. Malinowski, Separating Predictive Genetic Testing From
Snake Oil: Regulation, Liabilities, and Lost Opportunities, 41 JuRJMETRics 23, 31-33, 47 tbl. 1
(2000) [hereinafter Malinowski, Snake Oil]. See generally Aris Persidis, Biotechnology in a
Snapshot, 18 NATURE BioTECHNOLOGY IT2 (2000) (Industry Trends Supplement). The tech
nologies continue to evolve, and often in fundamental ways. For example, in March 2002,
United States patent 6,355,420 was issued for a new methodology to sequence DNA that
mimics nature's way of reading genetic information. See Teresa Riordan, Patents: An Ob
session with DNA and the Human Genome Leads to Development of a Technology, N.Y. TIMES,
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The pharmaceutical and biotechnology industries are utilizing ge
netics-based research to improve decision-making and to streamline
the drug development process, whic h has given rise to a field
known as pharmacogenomics.4

In simplest terms, pharmacoge

nomics is the "study of the impact of genetic c haracteristics on the
health care of populations who share the characteristic(s) at issue."5
Because of this approac h to drug development, society should antic
ipate the incremental market introduction of generations of drugs
with unprecedented genetic specificity and reduced side effects.6
These drugs will be acc ompanied by heavy utilization of genetic
profiling in the delivery of health care.7 Moreover, genetic profiling
will

be

used

increasingly to

improve

prescribing traditional

pharmaceuticals, and even to tailor some pharmaceuticals to accom
modate the genetic idiosyncrasies of individual patients.8

"The

study of the impact of genetic characteristics on the health care of
individuals who possess the characteristic(s) at issue" is a field
known as pharmacogenetics.9

Mar. 18, 2002, at C2 (profiling the work of Eugene Chan, founder and chairman of U.S.
Genomics).
4

Pharmacogenomics encompasses identifying cell function at the genetic level and using
predictable cellular response to chemical stimuli at the genetic level to drive drug develop
ment. See Malinowski, Snake Oil, supra note 3, at 49 tbl.2. This field is likely to accelerate
drug discovery and introduce some clinical trial cost savings, but it is also likely to divide
traditional disease classifications and shorten the market lifespan of drugs through the
more timely introduction of follow-on technology and market substitutes. See Michael J.
Malinowski, Institutional Conflicts and Responsibilities in an Age of Academic-Industry Alli
ances, 8 WIDENER L. SYMP. J. 47 n.21 (2001) [hereinafter Malinowski, Institutional Conflicts];
Ronald Rosenberg, Development of Drugs Seen Faster, Cheaper, BosTON GLOBE, June 5, 200t
at Dl-D2, available at 2001

WL 3936608; see also infra

Part III.C.2

(arguing that

pharmacogenetics is producing many challenges that the medical community will have to
face, such as forcing pharmacists and medical personnel to assume increased responsibili
ties). But see Arti K. Rai, The Information Revolution Reaches Pharmaceuticals: Balancing Inno
vation Incentives, Cost, and Access in the Post-Genomics Era, 2001 U. ILL. L. REv. 173, 173
(2001) (suggesting that cost savings from genomics will generate a market windfall that
should be used to "scale back" patent protection for pharmaceuticals).
5

See MalinowskC Snake Oil, supra note 3, at 49 tbl. 2.

6

See generally id. at 47 tbl. 1.

7

See Ge11etic Testing in the New Millennium: Advances, Standards, Implications Before the House
Subcommittee on Technology, 106th Cong., Apr. 21, 1999 (statement of Francis S. Collins); see
also Malinowski, Snake Oil, supra note 3, at 31-33, 49 tbl. 2; see also Leroy Hood & Lee
Rowen, Gmes, Genomes, and Society, in GENETIC SECRETS 21 (Mark A. Rothstein ed., 1997).

8
9

Malinowski, Snake Oil, supra note 3, at 31-33.
Id. at 49, tbl. 2; see also Sharon Begley, Made-to-Order Medicine, NEWSWEEK, June 25, 2001, at
65.
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Utilization of pharmacogenomics and pharmacogenetics raise
a multitude of law, policy, and market implications. These implica
tions include:

1)

A shift from decades of dependence on approximately

relatively crude pharmaceuticals derived from

483

3,000

drug targets for

the treatment of all human diseases to identification of between
and 10,000 drug targets for use in developing potentially tens

3,000

of thousands of drugs;10

2)

Intense demand for human biological samples and access to

pedigree and family histories;11

3)

Multiplication of the number of clinical trials and increased

participation in trials;12

4)

More direct communication between human subjects, trial

sponsors and investigators via Internet compilation and public dis
semination of clinical trial information;13

5)

Increased commercial pressures on industry and collabora

tors in academia and medicine and, consequentially, in the absence
of regulatory reform,14 raised risks to human subjects and research
integrity;15

6)

Heightened medical privacy concerns as

genetic

more

information will be

exponentially

obtainable from

individual

samples;16

7)

Fracturing of traditional disease classifications and recogni

tion of health conditions not yet fully identified;17

8)

Increased specificity in FDA drug labeling and restrictions

on approved uses;1s
lO

See

PHARMACEUTICAL

INDUSTRY

PROFILE

2001: A

CENTURY OF PROG RESS

ter PhRMA PROFILE 2001], available at www.phrma.org; PhRMA,
TRY

PROFrLE

14 (2001) [hereinaf

PHARMACEUTICAL

INDUS

2000 (2000) [hereinafter PhRMA PROFILE 2000]; Ronald Rosenberg, Data

Bottleneck Slowing Drug Discovery, BosToN

GLOBE,

June 20, 2001, at D4; see infra Part II

("Trends in Pharmaceutical R&D"); see generally ERNST & YoUNG, CoNVERGENCE: THE Bro

TECHNOLOGY INDUSTRY REPORT {2000).
11

See infra Part III.A.l ("Access to Human Biological Samples").

12

See infra Part III.B ("Metamorphosis of Clinical Research").

13

See infra notes 99, 125 and text accompanying notes 124-27.

14

See infra Part IV ("Proposals for Legislative and Regulatory Reform"); see generally Mali
nowsk i, Institutional Conflicts, supra note 4 at 64-73 (introducing proposals for regulatory
reform).

15

16
17
18

See infra Part III.A, III.A.l ("Access to Human Biological Samples"), Part III.A.2 ("Protection of Human Subjects"), and Part III.A.3 ("Conflicts of Interest").
See infra Part III.A.l ("Access to Human Biological Samples").
See infra Part III.C.2 ("Health Care Provider Competency").
See infra note 49 and accompanying text.
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9)

A surge in prescription drug prices and the intensity of cov

erage/reimbursement challenges resulting from allocation of higher
research

and

development

("R&D")

costs

to

smaller

patient

groups;19

10)

Pharmaceutical efforts to reach presently untapped mar

kets and to introduce preventive drug use t o offset market losses
attributable to the fracturing of traditional p atient groups (resulting
from division of tradition disease classifications) and increased pre
scription precision, which will introduce more new costs such as
those associated with genetic screening;20 and

11)

Greater public and political support for price controls on

pharmaceuticals because of a jolting rise in the prices of break
through new drugs and their delivery.21
This article probes select law, policy, and market implications
of utilization of genetic profiling in drug development and, conse
quentially, in the delivery of health care. Part I reflects upon tradi
tional pharmaceuticals and the changing pharmaceutical economy.
Part II identifies trends in pharmaceutical

R&D with

a focus on utili

zation of genetic profiling. Part III probes implications for the deliv
ery of health care and the roles of patients, research subjects, and
providers, including pharmacists, and Part IV introduces proposals
for responsive reforms.

I.

TRADITIONAL PHARMACEUTICALS AND THE CHANGING
PHARMACEUTICAL EcoNOMY
After decades of solid profitability, pharmaceutical business

plans to meet shareholder expectations based upon traditional rates

19
20

See infra Part TII.C.3 ("Market Acceptance and Patient Access").
See Malinowski, Institutional Conflicts, supra note 4, at n.21; Michael J. Malinowski, FDA

Regulation of Biotechnolog1) Products for Human Use, in 1 ENCYCLOPEDIA OF ETHICAL, LEGAL,
AND PoLICY IssuEs IN BIOTECHNOLOGY 215, 224 (Thomas J. Murray & Maxwell J. Mehlman

eds., 2000) [hereinafter Malinowski, FDA Regulation).
21

This sentiment in favor of price controls on pharmaceuticals was strong enough to prompt
the National Institute of Health

(NIH) to issue a report opposed to introducing additional
conditions on biomedical research funding. See generally DEP'T HEALTH & H uMA N SERVS.,
NAT'L lNST. OF HEALTH, NIH RESPONSE TO THE CONFERENCE REPORT REQUEST FOR A PLAN
TO ENSURE TAXPAYERS' INTERESTS ARE PROTECTED (July 2001), available at http:/ /www.nih.

gov I news/070101 w yden.htm; see also M ilt Freudenheim & Melody Petersen, The Drug

Price Express Has Run Into a Wall, N.Y. TIMES, Dec. 23, 2001, at 1 (reporting market resis
tance to expensive new drugs in the absence of significant clinical utility benefits to offset

price increases).
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of return have become uncertain if not wholly unrealistic.22 Many of
the industry's most profitable pharmaceuticals have gone off patent
in recent years, and more key patents are approaching expiration.23
Attempts by m embers of the pharmaceutical industry to extend
market control over their products have become fodder for contro
versy and litigation.24

Moreover, the generic drug industry has

grown into a large, competitive, and increasingly influential sector,
especially in an age of intense controversy over drug pricing. 25
Under the Hatch-Waxman Act,26 generic competitors are able to
enter the marketplace via

an

Abbreviated New Drug Application

("ANDA") by establishing bioequivalence27 with approved prod
ucts, rather than undertaking the more burdensome task of estab-

22

See Malinowski, FDA Regulation, supra note 20, at 224-25; see B os TON CoNSULTING GRouP,
THE PHARMACEUTICAL INDUSTRY INTO hs SECOND CENTURY: FROM SERENDIPITY TO STRAT
EGY

38-39 (1999). But see Virginia Munger Kahn, Managers Say this Decade Belongs to Health

Care, N.Y. TIMES, Jan. 6, 2002, at 20 (arguing that more biotechnology companies are ex
pected to post earnings in the next few years and the industry is still i n a growth phase).
23

Notable examples of major revenue-generators that have gone off patent in recent years
include Prilosec, AstraZeneca's drug to treat stomach ulcers, and Prozac, an anti-depres
sant that generated extraordinary revenues for Eli Lilly. AstraZeneca has attempted to
cushion its loss by introducing an allegedly improved version of Prilosec, Nexium, and
Lilly now has a weekly dose version of Prozac. For identification of other pharmaceutical
products losing patent protection from 2000 through 2003, including expiration date and
sales information, see RoBBINS-ROTH, supra note 2, at 164-165 tbl. 20.1.

24

For example, in December 2001, 29 attorneys general filed suit against Bristol-Myers
Squibb to release the company's market hold over Buspar, an anti-anxiety drug, so that
generic drugs could enter the market. See Kahn, supra note 22, at 20. Prior to this action,
the Federal Trade Commission, U.S. Attorney's Office in Boston, consumer coalition
groups, and class action lawyers (including attorney veterans of the tobacco wars) filed
various separate lawsuits against pharmaceutical makers. These suits were based upon
allegations that the companies inflated drug prices, and often claimed that the defendants
had been blocking the market introduction of generic versions of their medications. See
Michael J. Malinowski, Health and Human Services, in DEVELOPMENTS IN ADMINISTRATIVE

LAw AND REGULATORY PRACTICE 2000-2001 391-392 Oeffrey S. Lubbers ed., ABA 2002).
25

See Generic Pharmaceutical Association (GPhA), at www.gphaonline.org (noting that
while brand name prescription drugs represented 55% of all prescriptions, they consumed
more than 90% o f drug therapy dollars spent at retail).

26

Drug Price Competition and Patent Restoration Act of 1984 ("Hatch-Waxman Act"), Pub.

L. No. 98-417, 98 Stat. 1585 (codified i n scattered sections of 15 U.S.C., 21 U.S.C., 28 U.S.C.,
and 35 U.S.C. ). See generally John Hudson, Generic Take-Up in the Pharmaceutical Market

Following Patent Expiration: A Multi-Country Study, 20 lNT'L REv. L. & EcoN. 205, 211

(2000).
27

"Bioequivalence" means equivalence in the amount of active drug that a product provides
to the site of drug action. For more information, visit the FDA web site at www.fda.gov I
cder/handbook/bioequiv.htrn.
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lishing fundamental safety and efficacy.28 Generic manufacturers
thereby have the opportunity to enter the market without incurring
hundreds of millions of dollars in R&D costs-for example, the
costs associated with generating and processing often voluminous
clinical data from Phase I through Phase III trials to establish safety
and efficacy for market approval, and then follow-on

studies

("Phase IV data")-and without assuming the enormous risks, costs,
and time-consuming market development challenges undertaken by
drug innovators.29
Moreover, in spite of law reforms in favor of globalization of
life science markets such as enactment and implementation of the
General Agreement on Tariffs and Trade ("GATT") and Trade Re
lated Intellectual Property Sections

("TRIPS"),30 longstanding seams

among these global markets continue to unravel.

Although the

United States may remain optimistic about the promise of fully im
plementing GAIT /TRIPS by 2015, even among signatories with de
veloping economies, daunting challenges to global harmonization
continue to arise.31 GATT /TRIPS is being implemented in the con
text of increasing disparity in life science capabilities among devel
oped and developing economies, which is all the more difficult to
ignore in an age of unprecedented global communication, interna
tional travel, and shared, increasingly ominous epidemiological
challenges. The burgeoning biotech sectors of the United States and
Europe and the market availability of drugs such as Herceptin for

28

According to the Pharmaceutical Research and Manufacturers of America ("PhRMA"), the
amount of pharmaceutical sales allocated to R&D will have reached 18.5 percent in 2001
(compared with 17.4 percent in 1999), meaning that in 2001 the industry spent $26.3 billion
on R&D. See PhRMA PROFILE 2001, supra note 10, at ch. 2. According to PhRMA, the time
from synthesis of a new drug to market approval has stretched to 14.2 years in the 1990s.
Id. (relying upon data from the Tufts Center for Drug Development). For details regard

ing the FDA's r equirements to establish safety and efficacy for a range of products, see
www.fda.gov.
29 See supra note 28. See

also MICHAEL J.

ch. 11 (Aspen
tent of the phases).
REGULATION

30

Law

MALINOWSKI, BIOTECHNOLOGY LAw, BusiNEss,

&

& Business 1999 & Supps. 2001, 2002) (describing the con

Agreement on Trade Related Aspects of Intellectual Property Rights, Apr. 15, 1994, Mar
rakes h Agreement Establishing the World Trade Organization, Annex 1C, Legal Instru

ments-Results o f the Uruguay Round, val. 31, 33 I.LM. 81, 84 (1994) (expressing a desire
to reduce obstacles to international trade through protection of intellectual property
rights).
31

See generally Calestous Juma et al., Global

Governance o f

Technologt;: Meeti11g the Nee ds

of

Developing Countries, 22 INT. J. TECH. McMT. 629, 646 (2001); Jeffrey D. Sachs, Balms for the

Poor, THE EcoN O MIST, Aug. 14, 1999, at 63.
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an aggressive form of breast cancer,32 Cerezyme for Gaucher's dis
ease,33 Pulmozyme for cystic fibrosis,34 and protease inhibitors for
AIDS p atients35 are juxtaposed with the proliferation of deaths in
developing economies from highly preventable and treatable condi
tions such as basic nutritional deficiencies36 and malaria.37 Public
health and delivery of care inadequacies in countries such as the
Russian Republic, other former members of the Soviet Union, and
China are causing once treatable conditions such as tuberculosis to
take new, virulent and generally ominous forms.38

Even in the

shadow of impending GATT /TRIPS implementation, the wildfire
spread o f AIDS and associated deaths in African nations has re
newed demands for compulsory licensing of pharmaceutical-owned
32

Information about Herceptin is available at www.herceptin.com. Herceptin generally is
administered in combination with Taxol, and the total cost of this cocktail is approxi
mately $12,000 per patient for a six-month course ($6,000 per drug). See Beezy Marsh, The
Miracle Cocktail: New Drugs Cocktail Can Help Women to Live Longer, DAILY MAlL, May 16,

200t available at 2001 WL 21128992.
33

The world's most expensive medicine, Cerezyme, costs approximately $175,000 per pa
tient annually.

See Dan Gerstenfeld, Teva to Market Treatment for Gaucher's Disease,

}ERUSALEM PosT,
34

THE

Nov. 21, 2001, available at 2001 WL 6 617162.

Information about Pulmozyme may be obtained from its manufacturer, Genentech, Inc. of
South San Francisco, at www.gene.com. See J.D. Kleinke, The Price of Progress: Prescription
Drugs in the Health Care Market, HEALTH

AFF. 4360,

Sept. 1, 2001, available at 2001 WL

10696964 (including Pulmozyrne in a category of expensive new drugs that lower short
term health care costs but guarantee higher costs in the long run-"the economics of
smoking in reverse").

35 A

year's therapy in the United States costs approximately $8,000. See Latest Developments

in HIV Diagnosis and Treatment, PuLSE 60, Feb. 11, 2002, available at 2002 WL 13571781.
::16

Genetic modification, though opposed by many in developed economies, could prove a
cost effective means to overcome some of these public health challenges. For example,
golden rice is a genetically modified strain of rice designed to overcome debilitating vita
min

A

deficiency. See David Lague, Biotechnology, FAR. E. EcoN. REv. 34, Apr. 4, 2002,

available at 2002 WL-FEER 5169787.
37

"Of a total $70 billion spent on health care research worldwide in 1998, for instance, only

$100 million was set aside for malaria research (about a tenth of the cost of the U.S. De
partment of Defense's recent 'experiment' of intercepting a ballistic missile with a ground
launched exo-atrnospheric kill vehicle)." Rights of Access, 19 NATURE BIOTECHNOLOGY 693

(Aug. 2001).

Although highly treatable and preventable with contemporary therapeutics,

malaria remains pervasive in developing economies and, with AIDS and tuberculosis, has
become an international public health priority and the subject of a multibillion-dollar
global fundraising initiative-'The Global Fund to Fight AIDS, Tuberculosis, and Mala
ria," which is a private foundation. See Christopher Newton, HH Secy. Thompson to Visit

Afr ica,

AssociATED PRESS, Mar. 29, 2002,

available at 2002 WL 17189950; B ill Gates, Bono Call

on Leaders at World Economic Forum, M2 PRESSWIRE, Feb. 1, 2002, available at 2002 WL

4 1584 86.
38

'
m and is
'Tuber culosis is turning out to be one of the major killers of the new millenniu
of
Scourge
be
o
t
es
Continu
probably the most serious threat to public health after AIDS." TB
the Century, THE TIMES oF INDIA, Mar. 27, 2002, available at 2002 WL 17725854.
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intellectual property and inspired the government of South Africa,
with the implied support of the World Trade Organization, to
trump patent rights with public health overrides.39

The leading

AIDS drug manufacturers within the pharmaceutical industry have
made major concessions but have been unable to completely fend
off generic competitors.4° Consequentially, these nations have reaf
firmed the pharmaceutical industry's apprehensions about interact
ing with the governments of developing economies and widened
the life science gap yet further, thereby ensuring future disputes
over access to innovative pharmaceuticals and tensions over recog
nition of intellectual property rights. 41 The absence of meaningful
life science capabilities in many biologically diverse areas of the
world raises global susceptibility to public h ealth challenges.42
The pharmaceutical industry is responding to this plethora of
challenges by changing its methodologies and dramatically increas
ing the percentage of revenue allocated to R&D.43 The overall reve
nue allocated to R&D has risen from

1 1°/o

to 1 8. 5°/o over the last

twenty years,44 and overall pharmaceutical investment in R&D has
risen from approximately

$2 billion

in

1991

to

$30.5 billion in 2001.45

Nevertheless, the pharmaceutical sector's aggressive embrace
of the precision in drug development introduced through biotech
nology and fields such as pharmacogenomics will have market con
sequences for these multinational pharmaceutical behemoths whose
existence is premised upon voluminous market scale and products
39 Juma

et al., supra note 31, at 630; Donald G. McNeil Jr., New List of Safe AIDS Drugs, N.Y.

TIMES, Mar. 21, 2002, at A3 ("In a move that could help bring down the price of AIDS
medicines for poor countries, the World Health Organization today released its first list of
manufacturers for safe AIDS drugs, which included a Jarge Indian producer of generics

and three smaller European ones.").
40

See McNeil, supra note 39, at A3.

41

Cf. Juma et al., supra note

31, at 630; McNeil, supra note 39, at A3. For those who have not

participated directly in dispute resolution with African nations over this issue or accessed
full information about those deliberations, it would be presumptuous to declare that more
satisfactory, workable alternatives to this outcome were overlooked. Therefore, it must be
acknowledged that alleviating ongoing human suffering and death attributable t o AIDS in
developing economies and u ndertaking measures to contain the accompanying threat to
global public health at the present time by forcing industry concessions may justify esca
lating the longer-term challenge of closing the life science technology gap between devel
oped and developing economies.
42

See generally LAURIE GARRETT, THE CoMING PLAGUE (1994);

JuDITH MILLER,

STEPHEN ENGEL-

BERG, W ILLI A M BROAD, GERMS: BIOLOGICAL WEAPONS AND AMERICA'S SECRET WAR (2001).
43

See su pra note 28; see also Malinowski, Institutional Conflicts, supra note 4, at 48-49.

44

See PhRMA PROFILE 2001, supra note 10, at ch. 2.

45 See id.
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that generate billion-dollar revenue streams on an annual basis.46
As addressed below, decades of extraordinary profitability from
broad market exploitation, including extensive off-label use by phy
sicians, of pharmaceuticals developed from several hundred drug
targets to treat all human diseases is the past, not the future, of com
mercial life science. 47

II.

TRENDS IN PHARMACEUTICAL R&D
Traditional

pharmaceuticals are

understood largely

based

upon use in human subjects and patients-meaning clinical trials
and physician experiences that indicate which compounds alleviate
and/ or ameliorate symptoms associated with particular diseases.48
There

is

wide

variation

in

patient

responsiveness

for

most

pharmaceuticals, ranging from non-responsiveness to severe ad
verse events from the standard of care dosage. Consequentially:

1) Physicians have practiced broad off-label discretion, mov
ing use of most pharmaceuticals well beyond the clinical trial design
for safety and efficacy and resulting FDA labeling;49

2) Our aging population now is testing the limit of our knowl
edge about drug combinations and interactions;50

3) Dosage and drug combinations raise patient-by-patient
challenges for physicians;51

4) Estimates for the health care costs associated with unin
tended reactions to pharmaceuticals have reached as much as $100
billion annually;52 and
46

See Malinowski, FDA Regulation, supra note 20 at 224; Malinowski, Institutional Conflicts,
supra note 4, at n.21. See generally BosTON CoNSULTING GROUP, supra note 22, Chapter 3,

app.2.
47

See infra notes 151-154 and accompanying text.

48

See g ene rally BosTON CoNSULTING GROUP, supra note 22, app.2; PhRMA PROFILE 2001, supra
note 10, ch. 3.

49

Companies Balance Risks, Rewards
WL 12321164 .

50

M a ry Desmond Pinkowish, Prescribing for Older Patients: 5 Points to Remember, PATIENT

f Off-Labeling, FooD & DRUG LETTER, Mar.

o

15, 2002, 2002

C.to.RE 45, available at 2000 WL 100711936 (Aug. 15, 2000).
51
52

Id.
Althou gh the relia bilit y of the Institute of Medicine's 1999 report has been called into
question (available at www.IOM.edu), it is beyond dispute that medical mistakes are re
sponsible for th ousands of deaths per year. See Death Total from Medical Mistakes is a Matter

INDIANAPOLIS NEws/INDIANAPOLIS STAR, Mar. 31, 2002, at J01, available at 2002
WL 16980099; see also David Brown, The End of an Error? Big Business, Launching a New Era
o

f Dispute,

of Reform, is Pressuring Hospitals to Cut Mistakes, WASH. PosT, Mar. 26, 2002, at FOl, available
at 2002 WL 17585639. The problem is also pervasive outside of the United States. See

Hous.

40

5)
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Many prevalent diseases remain untreatable with tradi

tional pharmaceuticals.53
However, times are changing.

Through fields such as ge

nomics (identifying genes and gene function),54 proteomics (identi
fying protein function),55 and bioinformatics (the combination of
biotechnology and information technology),56 the pharmaceutical
industry anticipates churning vast amounts of data from volumi
nous numbers of samples and identifying as many as ten thousand
drug targets over the next several years.57 This expectation is pre
mised upon new sets of tools for discovering, mapping, and modi
fying genetic information-meaning tools for distinguishing gen e
expression and isolating which particular genes to study.58 Utiliza
tion of DNA chips, which are silicon chips embedded with multiple,
distinguishable bits of DNA, has made large-scale screening possi
ble.59 DNA chips can be used to test the samples of individuals for
Sarah Lyall, More Deaths In England Due to Error, Report Says, N.Y. TIMES, Dec. 20, 2001, at
A6 (reporting that approximately 1,200 people died in public hospitals in Britain last year
due to mistakes in prescribing and administering medications).

53 Harnessing Genes, Recasting Flesh, THE PHARMACEUTICAL CENTURY, available at http://pubs.
acs.org/joumals/pharmcent/Ch8.htrnl. In spite of the resources invested over the past
several decades to combat diseases responsible for the h ighest levels of mortality in the
United States, namely heart disease and cancer, those diseases remain formidable chal
lenges. As of March 2001, heart disease was responsible for 35% of all deaths among those
65 and older, and cancer was responsible for 22% of the deaths in this age group. CTRS.

FOR DISEASE CONTROL AND PREVENTION, NAT. CNTR FOR HEALTH STATISTICS, TREN DS IN

CAUSES OF DEATH AMONG

THE

ELDERLY available at www.cdc.gov/nchs/data/aging

trends I 0 I death. pdf .
54

Malinowski, Snake Oil, supra note 3, at tbl. 1.

55 Id. at tbl. 2. IBM's Blue Gene can crack the genetic code for proteins from start to end. Eric
Stawiski, The Biologist Meets the Computer Scientist, WoRLD & I, Mar. 1, 2002, p. 137143,

available at 2002 WL 9015548. For an illustration of how IBM is using its supercomputing
technology for biomedical research, see IBM/Physiome Sign Supercomputing/Biological Model

ing Pact, M AI NFRAME CoMPUTING (Oct. 1, 2001), available at 2001 WL 12586424.

56 Malinowski, Snake Oil, supra note 3, at tbl. 1.
57 See supra note 10 and accompanying text. As stated earlier, the approximately 3,000 tradi
tional pharmaceuticals on the market have been developed from just 483 drug targets.
PhRMA, INDUSTRY PROFILE 2001, supra note 10, at v.
58

See generally Malinowski, Snake Oil, supra note 3 at 31-33; PhRMA, INDUSTRY PROFILE 2001,

supra note 10 at ch.9; see BosTON CoNSULTING GRoUP, supra note 22, at 53-55, app.l.
59

The basic methodology is to use the process of hybridization (predictable nucleotide bond
ing between A&T, C&G) and probes-short nucleotide chains that have a signaling en
zyme that glows when the probe hybridizes (i.e., the gene of interest is present)-to isolate
and identify instances of genetic expression. RoBBINs-RoTH, supra note 2, at 73-74. Today,
scientists are able to access commercial DNA chips with the capacity to screen for more
than 6,000 specific genetic sequences (DNA arrays). Malinowski, Snake Oil, supra note 3, at
32. Affymetrix has introduced a commercial chip with the capacity to screen for 400,000+
arrays by 2003 (a 1999 prediction that may already have been realized). See RoBBINs-RoTH,
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the p resence of thousands of identified genetic variations and, alter
natively, to screen hundreds of thousands of individuals with a
shared phenotype characteristic to isolate and identify shared ge
netic expression. This tec hnol ogy has made it feasible to do com
prehensive gene expression comparisons among large group s of
people-e.g.,

a

well-documented

disease

group

such

as

the

Framingham heart study patien ts, or even the population of Ice
land.60 In fact, b ioinforma tics capa bilities have inspired the forma
tion of a consortium among pharmaceu tical, biotech, and academic
participants to compile data on the impact of variations of single
nucle otide p olymorphisms (SNPs), meaning single letters in the

DNA

bluep rint-a denine

("A"),

cytosine

("C"),

guanine

(

"

G

"

)

,

or

thytosine ("T")-on susceptibilities to diseases and responsiveness
to prescrip tion drugs and/ or drug combinations.61
One consequence of this approach to pharmaceutical R&D is
unp recedented p re cision. Reflective of this trend, those engaged in
contemp orary life science R&D have b een filing a deluge of p a tent
app lication s.62 More p rofound from a human health perspective, in
du stry app lica tion is closely trailing the advancement of contempo
rary life science and, in turn, industry is financing and a dv ancing
this field of science-thereby mov ing u s into an era of genetic p reci
sion in pharmaceutical development and prescription drug deliv-

supra note 2, at 73-81; see also David Stipp, Gene Chip Breakthrough Microprocessors Have
Reshaped

our

Economy, Spawned Vast Fortunes and Changed the Way We Live.

Gene Chips

Could be Even Bigger, FoRTUNE, March 31, 1997, at 56.
60
61

See infra notes 115 and 148.
See Orchid Biosciences, Inc., at http://www.orchid.com. Consider that, if each nucleotide
base l etter in y o ur DNA blueprint was the size of a letter in standard typewritten text,
your DNA blueprint would be a sentence spanning from Portland, Oregon to Chicago,
Illino is. A SNP is just one of those billions of letters. Tom Abate, The Gene Age/Inside Our
selves/Two Groups on Verge of Reading the Entire Human Gene Code, S. F. CHRON., Apr. 25,
2000, at Al.

62

J. Malinowski, The Commodity of Intellectual Property in the Risky Business of Life
Science, 41 JuruMETRics 414 & nn. 33-34 (1999) (book review essay). The PTO now issues
See Michael

70% more patents-approximately 170,000 in 1999-than it did a decade ago. See UNITED
STATES PATENT & TRADEMARK OFFICE, Annual Reports: 1999 Annual Report, available at
http://www.uspto.gov/web/offices/corn/annual/index.html; see also Peter Coy, The 21st
Century Corporation, Bus. WEEK, Aug. 28, 2000, at 78. Patent applications for biotechnol
ogy, organic chemistry, and pharmaceuticals have nearly doubled from 1996 to 2000

(rea ching 32,705 in 2000), and approximately two-thirds of the 2000 a pplications were for
genomics patents. See UNITED STATES PATENT & TRADEMARK OFFICE, Annual Reports: 2000

Annual Report, available at http: 11 www.uspto.govI webI off ices I com/ annual/index.html.
The PTO has added 800 examiners and estimates a 25% increase in filings for 2001.
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ery.63 Consequentially, genetic testing is entering the medical
setting as an accompaniment to drug delivery.64 For example, in
1998, Genentech, Inc. (South San Francisco, CA) introduced Hercep
tin into the marketplace for women with an aggressive form of
breast cancer who also have over-expression of Her-2 neu; the mar
ket entry of Herceptin was accompanied by the commercial availa
bility of a test to screen for over-expression of Her-2 neu.65 In
January 2000, Visible Genetics Inc. (Toronto, CA) received national
coverage approval from France for a genotyping kit for HIV that
assists doctors in making the best use of available medicines.66 In
2002, the FDA approved the test for the U.S. market.67 In addition,
Virologic (South San Francisco, CA) is manufacturing a homebrew
version of this test, which enables patients and their physicians to
determine whether they are infected with d rug-resistant strains of
HIV.68
The research community, medical community, and even the
general public should anticipate access to more pharmacogenomic
testing capabilities in the foreseeable future. 69 In fact, companies
such as Orchid Pharmaceuticals (NJ), Pangea Systems, Inc. (Oak
land, CA), and HySeq Inc (Sunnyvale, CA) have announced inten
tions to make information about genes available over the Internet
for researchers first, and ultimately for consumers.70 Prior to his de
parture from Celera, Inc.,71 the company that challenged the U.S.
63

See generally Malinowski, Snake Oil, supra note 3, a t 26; PhRMA PROFILE 2001, supra note 1 0
at ch.2; PhRMA PROFI LE 2000, supra note 10 at ch. 2.

6.J

See generally Malinowski, S nake Oil, supra note 3.

65

See ge11erally RoBERT BAZELL, HER-2: THE MAKING OF HERCEPTJN, A REVOLUTIONARY Tr{EAT
MENT

FOR BREAST CANCER 175-186 (1998); see also FDA Approves DAKO Herceptest to Identify

Potential Patients for Herceptin, the New Breast Cancer Treatment Drug from Genentech, Bus.
WIRE 20:26:00 (Sept. 25, 1998).
66

See Andrew Pollack, When Gene Sequencing Becomes a Fact of Life, N.Y. TIMES, Jan. 17, 2001,
at C1; see also Malinowski, Snake Oil, supra note 3, at 31 n.31.

67

See Visible Genetics Inc., FDA Grants Market Clearance of HlV Genotyping System, BrolNDEX,
(Apr. 10, 2002), available at 2002 WL 18689534; see also Tom Abate, The Economics of Genetic

Testing/The Race to Develop New Ways to Detect Disease is As Much About Cost as it is About
Technology, S.F. CHRON., Feb. 10, 2002, at G1, at 2002 WL 4012496 (detailing information on
the strengths and weaknesses of Celera).
68

See id.

6q

See generally Malinowski, Snake Oil, supra note 3, at 32-33.

70

See id.

71

David Shook, Celera: A Biotech That Needs a Boost: The Onetime Genomics Highflier has to

Replace Departed Founder Craig Venter and Ramp Up Its Drug Development Unit, Bus. WEEK,
Mar. 1, 2002, available at 2002 WL5145033.
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government-headed initiative in a race to map the human genome,72
founder Craig Venter stated that the ultimate Celera consumer
would be the individual who will access the company's databases to
get information about him or herself and make more informed
health care decisions.73 Some companies already have moved for
ward with business plans premised upon genetic profiling and di
rect-to-consumer interaction. For example, in the Summer of 2000,
DNA Sciences launched a Web site to recruit people to donate their
DNA to help identify genetic variations that cause disease, thereby
compiling a database gene trust, a large statistical sample.74 In De
cember 2000, DNA Sciences acquired PPGx, which had announced
plans in the Fall of 2001 to offer a genetic test, the 2D6 test, directly
to the public .75 The 2D6 test identifies the approximately ten per
cent of the population who are poor metabolizers of a broad array of
prescription drugs_76

III.

IMPLICATIONS FOR THE DELIVERY OF HEALTH CARE AND
THE

RoLES OF PATIENTS, REsEARCH SuBJECTS,

AND PROVIDERS
The shift from decades of dependence on pharmaceuticals
crude by contemporary standards to generations of pharmaceuticals
developed from potentially ten thousand plus drug targets77 will
prove an impetus for ongoing changes in life science methodology.
Genetic precision in drug development also will impact the prac
tices and roles of commercial sponsors, research subjects, patients,
and health care providers .
A.

Basic Life Science R&D Impl ications

As stated above, in contem porary biomedical science, increas
ingly, less means more. Scientists have long appreciated that all di72

See supra note 1 .

73

Lawrence M. Fisher, Surfing the Human Genome: Data Bases of Genetic Code Are Moving to the
Web, N.Y. TIMES, Sept. 20, 1999, a t C1. Subsequently, Venter has moved on to found two
institutes. See Nicholas Wade, Thrown Aside, Genome Pioneer Plots a Rebound, N.Y. TIMES,

Apr. 30, 2002, at 01, D6.
74
75
76

DNA Science s, at http : / /www.dna.com.

DNA Sciences Inc., MEo Ao NEws, Aug. 1, 2001, at 16, available at 2001 WL 26968874.

WL 242 1 851 9;
David Stipp, A DNA Tragedy, FoRTUNE, Oct. 30, 2000, at 170, available at 2000
Cinda Becker, Special Report: The DNA Rx, MoDERN HEALTHCARE, Aug. 28, 2000, at 24,

available at 2000 WL 8169272.
77

See supra note 10 and accomp anying text.
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versity within the human species is attributable to a mere . 1 percent
of DNA.7B However, in March 200 1, the science community deter
mined that the human genome consists of approximately thirty
thousand genes rather than the eighty to one hundred fifty thou
sand genes estimated throughout most of the 1990s.79 Presumably,
individual genes do much more than anticipated before this count
adjustment, meaning that gene function is a more intricate and com
plicated series of processes than previously appreciated.
The resulting reduction in scale and heightened intricacy in life
science suggests that patenting at the level of expressed sequence
tags ("ESTs") and single nucleotide polymorphisms ("SNPs") is
likely to increase even in the face of higher USPTO standards for
utility and written disclosure.80 Other readily apparent implications
of this heightened intricacy in life science R&D and utilization of
bioinformatics include raised demand for human biological samples
and access to pedigree information and family histories,81 intensi
fied commercial pressures on both industry and academia in an age
of academic-industry collaborations and increasingly pervasive con
flicts of interest that threaten the safety of research subjects and the
integrity of data, 82 continued multiplication in the number of clinical
trials initiated and more demand for trial subjects,83 and more direct
communication between research sponsors and potential research
participants to access both samples and subjects.84

1.

Access to Human Bio logical Samp les
Many tracks of drug development research, including research

u tilizing pharma cogenomics, are dependent upon access to vast
78

See www.arrmh.org/ exhibitions/ genomics; see also Francis S. Collins et al., New Goals for
the U.S. Human Genome Project: 1998-2003, 282 SciENCE 682, 683 ( 1998).

79

Gene Weingarten, Genetic Leftovers: Those Extra DNA Strings May Hold Keys to Oddities,

Hous. CHRON., Mar. 23, 2001, at 1, available at 2001 WL 3007837.
110

ln January 2001, the agency announced new "Utility Examination Guidelines" and "Writ 
ten Description Guidelines'' intended to make it more difficult to paten t genes. See Utility
Examination Guidelines, 66 Fed. Reg. 1092-1099, 1097-99 (Jan. 5, 2001) (setting forth spe
cific standards); Guidelines for Examination of Patent Applications Under the 35 U.S.C.

§

112, P1, "Written Description" Requirement, 66 Fed. Reg. 1099 (2001). These guidelines

clarify that a claimed invention must have

a

specific and substantial utility that is credible

or a readily apparent, well -established utility. See 66 Fed. Reg. at 1092-1099 (2001).
til
82

See i11jra section III.A .1.
See infra sections III.A.2., III.A.3.

1n

See infra section III.B.

84

See i11jra notes 99, 1 25 and accompanying text (identifying web sites that make clinical trial
information directly accessible by the general public).
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numbers of hutnan subject samples and the resulting data.85 In fact,
as discussed in Part II, ongoing scientific and com mercial enthusi
asm at the forefront of life science now centers on technical capabili
ties-microarrays, DNA chips, and other enabling technologies
that exponentially increase the number of human biological samples
that can be run and the amount of data that can be generated and
processed.86 The capability to run many thousands of genetic com
parisons in the matter of minutes has j olted scientific and commer
cial

detnand

to

access

and

compile

large-scale

population

databases.87
The disconnect between the Clinton Administration and the
Bush Administration has left unanswered many framed, highly con
troversial life science and health care policy and regulatory ques
tions that may linger for years in spite of the intensity of the
ongoing genetics revolution.

One such question is whether the

Common Rule88 will be expanded to encompass all human subject
research, perhaps based upon the Commerce Clause,89 rather than
just federally funded research.9o Another is whether "human sub
jects research" will be interpreted to include samples encrypted but
ultimately identifiable.91
85

See generally supra notes 54-61 and accompanying text (discussing trends in R&D that re
flect these demands).

86

S ee id.

87
&!

See id.
The Depa rtment of Health and Human Services' policy to protect human subjects, known
as the Common Rule, is codified at 45 C.F.R § 46 (2000). For a technical discussion about

human subject protection regulations and their implementation, see MICHAEL J. M ALIN OW
SKI, BIOTECHNOLOGY: LAW, B USINESS, & REGULATION § 9.02 (Aspen Law & Business 1999 &

Supps . 2001, 2002); see generally PrucEWATERHOUSE CooPERS, LLP, INSTITUTIONAL REFER
ENCE BoARD (IRB) REFERENCE BooK (Michele K Russell-Einhom & Thomas Puglisi, eds.,

2001 ).

R9 U.S. CoNsT. art. 1 , § 8, cl.3.
90

S ee NATIONAL B roETHrcs ADvisORY CoMMISSION, RECOMMENDATIONS: En-neAL AND Poucv
IssuEs IN RESEARCH INVOLVING Hu MAN PARTICIPANTS (May 18, 2001) [hereinafter NBAC
Recomrnendations ] (proposing the establishment of one single, independent federal office to

implement a unified, single set of regulations and guidance), available at http:/ /bioethics.
georgetown.edu/NB AC/pubs.html; see also Ethical and Polietj Issues in International Re
search : Clinical Trials in Developing Countries (Apr. 18, 2001) (addressing whether U.S. re 
lations remain approp riate in the context of international research and the changmg

�

land scape of international research due to pressures on private companie s to become more
efficient in the conduct of research), available at http:/ /bioethics.gov I clinical/ ·

91

See NBA C Re commendation s, su pra note 90. The primary regulatory issue is whether en
cryp ted human biological samples will be treated as the equivalent of identifia le sa�ples
.
and therefore be fully subjected to the requirements of informed consent and mstituho�al
rev iew board ( IRB) oversight. ee 45 C.P.R. § 46.101 (2000) (referring to DHHS' protection
S

�
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During the Clinton Administration, the anticipated expansion
and meaningful enforcement of human subject protection regula
tions and debate over the implementation of the Health Insurance
Portability and Accountability Act

("HIPAA")92

raised the commer

cial viability of companies in the business of providing an "ethically
sound" alternative to the vast human biological material reposito
ries compiled over the last several decades .93 However, in March
2002, the Bush Administration discarded the HIPAA informed con

sent requirement as "unworkable," thereby alleviating some imme
diate

angst

in

the

health

care

delivery

and

life

science

communities.94 Nevertheless, given the timeline for developing a
pharmaceutical,95 there now is regulatory pressure on those en
gaged in life science R&D to either use wholly unidentifiable sam
ples or to introduce significant complexity and expense-e. g. ,
purchase the services of commercial suppliers of human biological
materials-which presumably will be folded into escalating drug
costs. In the absence of implementation and enforcement of reliable
regulatory safeguards around sample collection and use that ensure

for human subject regulations); 21 C.F.R. 50.20 (200 1 ) (referring to FDA informed consent
regulations). See also DEP'T OF HEALTH & HuMAN S ERV S . , OFFICE FOR HUMAN RESEARCH
PROTECTfONS, COMPLIANCE OVERSIGHT PROCEDURES (2000), at http:/ /www.ohrp.osophs.
dhhs.gov I compovr.htm.
42 HHS Proposes Changes that Protect Privacy, Access to Care; Revisions Ensure Privacy Protec
tions, Removing Obstacles to Care,

U.S. NEWSWIRE, Mar. 21, 2002, 2002 WL 4575666 [hereinaf

ter HHS Proposes Changes] .
93

Examples of these commercial suppliers include The First Genetic Trust, available a t www.
firstgenetic.net, and Genomics Collaborative, Inc., available at www.dnarepository.com.
See Jeffrey Krasner, Gene Pooling: Company Bu ilds World's Largest Library of Genetic Material,
BosTON GLOBE , Aug. 22, 2001 , at Fl. Many of the hundreds of millions of samples held in
preexisting repositories were collected during the course o f routine diagnostic and medi
cal procedures under a theory of medical waste and donor abandonment and without
meaningful consent. Eric Niiler, Surgical Refuse is Research Treas ure, THE S.D. UNION-Tl{IB
UNE, Dec. 6, 2000, at Fl. In addition to commercial suppliers, some teaching hospitals are
compiling central tissue banks with contemporary informed consent practices to become
future suppliers. See Jeffrey Krasner, Partners HealthCare Planning Tissue Bank: Hospital
Group Cites Research Potential, BOSTON GLOBE, Sept. 4, 2001, at Dl.

94

note 92. Subsequently, the Bush administration changed
the burden for collecting written informed consent to notice of privacy policies. See Jen
nifer Kulynych & David Korn, Use and Disclosure of Health Information in Genetic Research:
Weighing the Impact of the New Federal Medical Privacy Rule, 28 AM. J.L. & MEo. 309, 322-23
(discussing the ramifications of the proposed rule changes); see also 45 C.F.R. § 1 64.508
(2002) (reflecting that these policy changes become effective on Oct. 15, 2002).

9:;

See supra

See HHS Proposes Changes, supra

note 28 (PhRMA estimates that, during the 1990s, the time required to develop a
new drug stretched to more than 14 years).

MALINOWSKI

47

accountability to sample donors,96 the ability to generate exponen
tially more genetic information from a given sample will affirm and
heighten medical privacy concerns.97

Protection of Human Subjects

2.

Meaningful pharmacogenomics research is expensive, a s are
human clinical trials.98 Even if pharmacogenomics can streamline
trials, today, many more trials need financing.99 The pressure from
shareholders to generate favorable data and to introduce break
through drugs to offset the loss of billion-dollar revenues due to
patent expirations has heightened over the last few years, and the
pressure continues to rise .100
The United States' framework to protect human subjects and
complementary agency policies and enforcement practices1 01 gener-

96

Implementation of the HIPAA regulations will increase medical privacy protections but, at
this time, whether these protections will offset the increased flow of genetic information
remains an open question, especially since the Bush Administration has discarded the in
formed consent provision. See supra note 94.

97

See generally Chris Meyers et al., Genomics: Implications for Health Systems/ The Effect of Ge
nomics on Health Services Management: Ethical and Legal Perspectives, 1 7 FRONTIERS

oF

HEALTH SERV.S MGMT. 316 (2001).
98

See Malinowski, Institutional Conflicts, supra note 4, a t n.94 (noting physicians may be paid
reimbursement fees of thousands of dollars per patient). The "American Association of
Health Plans generally encourages reimbursement for the routine costs of care associated
with NIH-sponsored trials, and several large private health plans have been routinely cov
ering cancer research trials conducted by the National Cancer Institute." Id. at 55; see gen
erally Francis H . Miller, Trusting Doctors: Tricky Business When It Comes to Clinical Research,
81 B.U. L. REv. 423, 425 (2001) (stating that "some drug and device manufacturers now
compensate primary care physicians for enrolling their patients in clinical studies").

99

See Malinowski, Institutional Conflicts, supra note 4, at n.l and accompanying text. To learn
what is transpiring in the clinical trial segment of the drug development pipeline, see
http: / I clinicaltrials.gov

(detailing

approximately

5,500

mostly

government-funded

clinical trials); http: I I cancer. gov j clinical_trials (exhibiting the Na tiona! Cancer Institute' 5
clinical trial listing); http:/ j actis.org (the AIDS Clinical Trials Information Service (AC
TIS)); http : / /www.veritasmedicine.com (listing trials and standard treatments for numer
ous diseases); http : / /www.americasdoctor.com/clintrials/main.cfm (showcasing trials in

100

101

seven disease categories, excluding cancer); and http:/ /www.acurian.com/patient (devel
oping lists of trials i n various disease categories) .
Model
See Steven R. Salbu,
Regulation of Drug Treatments for HN and AIDS: A Contractarian
of Access , 1 1 YALE J.
experimen
ON REG. 401, 442-43 (1994) (describing the need for private
tal drug comp anies
supra
to develop sales revenues and make a reasonable profit). See

notes 22-25 and accompa
nying text.

For discussi
on of the fundamental framework to protect human subjects (e.g., the Com
mon Rule, the
Institutional Review Board (IRB) system, and the Office o f Human Research
Protections (OH
RP)), see generally MALINOWSKI, BroTECHNOLOG Y, supra note 88; IRB REFER
ENcE Boox, sup
ra no te 88.
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ally predate the pervasive integration of academia and industry as
sociated

with

contemporary

life

science.l02

These

regulatory

regimes rely far too much upon self-compliance by institutions,
which in turn defer to and depend upon self-compliance by the in
dividuals engaged in the research that is supposed to be p oliced . 103
Institutional p olicies, to the extent meaningful policies even exist,104
lack specificity regarding permissible relationships and p ractices
and depend far too heavily upon disclosure to manage conflicts.105
During the twilight of the Clinton Administration, sweeping
bioethics reforms were proposed for human clinical trials. For ex
ample, in May

2000, the Clinton Administration released a plan to

improve patient safety in clinical trials that calls for clear conflict-of
interest guidelines for doctors who stand to make money on their
research. 106

In May 2001, the National Bioethics Advisory Commis

sion ("NBAC") proposed establishing a single, independent office
with jurisdiction over all (privately-funded, as well as federally
funded) domestic human subjects research with a single set of
rules.l07 Similarly, Dr. Greg Koski, Director of the Office for Human
Research Protections (OHPR) in HHS, called for the introduction of
universal standards for IRBs.1os
President Bush did not appoint leadership for the Food and
Drug Administration and National Institutes of Health until Febru102

See generally Malinowski, Institutional Conflicts , supra note 4, at 69 (noting the integration of
academia and industry have increased productivity and patient care).

103

See id. at 64 (explaining the regulatory scheme in the United States and its low level of
accountability due to reliance on self-compliance).

104

See generally id. at 66 (describing the majority of United States policies as ineffective). See
generally id. at 66 (describing the majority of United States policies as ineffective).

105

See generally Mildred K. Cho et al., Policies on Faculty Conflicts of Interest at US Universities ,
284 JAMA 2203, 2208 (2000) (reporting on an empirical survey indicating that the vast
majority of research institutions have failed to establish relevant policies because the poli
cies lack specificity).

106

See PRESS RELEASE, DEPARTMENT OF HEALTH AND HUMAN SERVICES, SECRETARY SHALALA
BoLSTERS PROTECTIONS FOR HuMAN RESEARCH SuBJECTS (May 23, 2000), available at http:/ I

www.hhs.gov / news/press/ 2000pres/20000523.html (noting policies will be developed to
require disclosure of financial interest in a clinical trial to potential participants); Donna
Shalala, Protecting Human Subjects-What Must Be Done, 343 NEw ENG.

J. MED.

808, 809

(2000).
107

See NBAC Recommendations, supra note 90 (proposing the establishment of one indepen
dent federal office to implement a unified, single set of regulations and guidance), available

at http: I /bioethics.gov I press/ finalrecomm5-18.html.
108

See OFFICE FOR HUMAN RESEARCH PROTECTIONS (OHRP) DIVISION OF ASSURANCES AND
QUAUTY IMPROVEMENT, QUALITY IMPROVEMENT PROGRAM (April 15, 2002), at http : / /ohrp.

osophs.dhhs.gov /humansubjects/qip/qipdesc .pdf.;

see

generally

http:/ / ohrp.osophs.

dhhs.gov /references/ koskibio.pdf (detailing the biography of Dr. Greg Koski).
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ary and May of 2002, respectively, and subsequently these agencies
presumably have merely shifted from limbo into a period of transi
tion. 109 Although President Bush has established a new Council in

Bioethics, thus far, this commission has fixated on the issue of
human cloning . 1 1 0 Nevertheless, research continues to rage onward,
with increased utilization of genetic profiling .I1 1 Never have as
many clinical trials been underway, and pharmacogenomics is be
ing embraced in clinical research to streamline both costs and
time 112 In fact, clinical research sponsored by U.S. companies to ad
.

vance pharmacogenomics has become a b ur geoning
deavor .

Examples

include

Millennium

,

global en

Pharmaceuticals'

undertakings in China, which has triggered considerable anxiety
over human subject participation, 1 1 3 and the joint venture in Japan
by Variagenics and Covance in November 2000.114 Similarly, Ice
land's DeCode Genetics, which has collaborations with several U.S.
interests, has

established Encode,

a

subsidiary specializing in

pharmacogenomics studies.115

109

Lester M. Crawford, Jr. was appointed to serve as FDA Deputy Commissioner on Feb. 25,
2002. See DEPT. oF HEALTH AND HuMAN SERVICES, Lester M. Crawford Jr. Named FDA Dep

uty Commissioner (Feb. 25, 2002) available a t http : / / www.hhs.gov /news/press/2002pres/
20020225.html. Elias Adam Zerhouni was appointed to serve as the Director of the NIH
on May 20, 2002. See NIH, Zerhouni Assumes Leadership of the National Institutes of Health
no

111

112

113

114

115

(May 20, 2002), available at http: / /www.nih.gov /news/pr/may2002/od-20.
The Preside nt's Council on Bioethics, available at http:/ /bioethics.govI (describing their
meeting agendas for February and January 2002, which covered the issue of cloning).
See generally Malinowski, Snake Oil, supra note 3, at 31-33 & app. tbl. 1 (analyzing the uses
of genetic profiling ) . See also supra Part II.
Malinowski, Institutional Conflicts, supra note 4, at n.1; Malinowski, Snake Oil, supra note 3
at 33. See also Ann M. Thayer, Biolnformatics for the Masses, CHEMICAL & ENGINEERING
NEws, Feb. 7, 2000, at 19 (discussing the use of software tools to capture data, which de

creases costs and improves use of the data collected in research).

See John Pomfret, Harvard Rebukes Head of China Gene Study, WASH. PosT, Aug. 9, 2001, at
A14 (noting the allegations about a Harvard professor's human-subject research, includ
ing allega tions of taking blood from Chinese farmers without informed consent and not
providing promised medical care).
See Covance Eyes Pharmacogenomics Business in Japan, CHEMICAL Bus. NEWS BASE, Nov. 24,
2000, at 1 2 (stating that a joint venhlre between two U.S. companies, Variagenic� and
Covance, was formed "to provide services to Japanese pharmaceutical producer s mter�
ested in overseas clinical development activities") .
also as having
See Decode Genetics,
Inc., available at www.decode.com (describing DeCode
established DeCod e Cancer to commercialize diagnostics and therapeutics).
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3.

Conflicts of Interest
The inclusion of a conflicts of interest provision in the U.S. reg

ulatory regime-a compliment and extension of regulations for
technology transfer, to protect human subjects, and to ensure re
search integrity-places tremendous reliance on self-policing by
principal investigators and their institutions.116 Trust is a questiona
ble assurance mechanism to police researchers and institutions ex
to

posed

incentives

commercial

such

as

royalty

equity

and

interests.117 C ontemporary commercial influences, including heavy
dependence upon industry for financing, application expertise, and
access to a multitude of proprietary enabling teclmologies, also have
exacerbated a preexisting entanglement of non-financial pressures:
These pressures, not primarily financial, include the desire for
faculty advancement, to compete successfully and repetitively for
sponsored research funding, to receive accolades from professional
peers and win prestigious research prizes, and to alleviate pain and
suffering . . . All of these nonfinancial pressures may generate con
flicts by creating strong bias toward positive results, and all of them
may more powerfully influence faculty behavior than any prospect
of financial enrichment.118

To support academic-industry synergies moving forward, rele
vant regulatory regimes must be strengthened. This observation
has been made all too evident in recent years by controversies in
cluding the death of human subjects given less than forthright infor
mation about adverse events in primate and even other human
studies,119 instances of doctors enrolling and treating patients in
1 1 <> Federal

thresholds have been established by the Department of Health and Human Ser

(DHHS), National Institutes of Health (NIHt to define "significant financial interest."
See 42 C.F.R. § 50.603(1), (3)-(5) (2000) (defining a "significant financial interest" as "any
thing of monetary value, including, but not limited to, salary or other payments for ser
vices

vices . . equity interests. . . and intellectual property rights," but not including aggregated
.

payments of $10,000 and/ or ownership interest in excess
C.F.R.

§§ 54.1-54.6

of

5% in a single entity); 21

(200 1 ) (outlining financial disclosures b y clinical investigators through

the FDA). See Malinowski, I11stitutimral Conflicts, supra note 4, at 72-73 and accompanying
text (addressing both NIH and FDA guidelines). However, the agencies rely heavily upon
institutions to actually manage conflicts. ld. at 69.

1 1 7 See ge11erally

Malinowski, l1rstituticmal Conflicts, supra note 4, at 58 (discussing that univer

sity audits are rare in a system of heavy reliance on individual researcher oversight).

1 111 David
1 1" Sec

Korn, Conflicts of lnterest i11 Biomedical Research, 284 JAMA 2234 (Nov. 1, 2000).

Gelsinger v. Trustees

County,

[

filed

Sept.

18,

of

the Univ. of Pa., Case No. 0009018885 (Ct. Com. Pl., Phila.

2000), at

http:/ / www. sskrplaw.com/links/healthcare2.html

Gelsinger Complaint"]. Following the death

..

of Jesse Gelsinger, the American

Society of

Gene Therapy (ASGT) prohibited researchers from taking equity interests or stock options
in companies which sponsor the researchers' gene therapy trials. Furthermore, the
ation of American Medical Colleges (AAMC) announced the
add ress conflicts

of interest issues, and

the

formation

Associ

of a task force to

American Medical Association (AMA)

adopted
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clinical studies paid for by the companies they own,120 disputes be
t ween academics and their industry sponsors over data,121 and pres 
sures on universities to loosen conflict-of-interest rules. 1 22 In the
absence of significant regulatory reform, escalating commercial
pressures will
integrity . 1 23
B.

increase risks to human subjects and

research

Metamorphosis of Clinical Research
Genetic precision in bench research is rapidly spilling over into

clinical

trials,

where

experimentation

and

treatment

(meaning

clinical research and clinical care) are integrating.124 Clinical re
search has entered an era of transp arency, meaning that information
about clinical trials is online and accessible to the general public,
and the public is seeking access. 1 25 As breakthrough treatments for
presently untreatable conditions mature in the drug development
a policy on conflicts of interest calling on all medical centers to develop guidelines to

avoid perceived and actual conflicts. See AMER. Soc " v OF GENE THERAPY (ASGT), Poucy
A MER IC AN SociETY

OF THE

oF

GENE THERAPY oN FINANCIAL CoNFLICT OF INTEREST IN

CLINICAL RESEARCH (2000), at http : / /www.asgt.org/policy/ index.html; AM. MEo. Ass'N,
COUNCIL ON ETHICAL & jUDICIAL AFFAIRS, CONFLICTS OF INTEREST: BIOMEDICAL RESEARCH,
Or. E-8.031 ( 1 999), at http : / /www.ama-assn.org /apps/pf_online/ . . . TM&hxt_pol=policy
files/CEJA /E-8.01 .HTM&; M alinow ski, btstitu ti01zal Conflicts, supra note 4, at 69-70.
120

See Gelsinger Compla int, supra note 1 19; see also Sheryl Gay Stolberg, Biomedicine Is Receiv

ing New Scruti11y as Scimtists Become Entrepreneurs, N.Y. TIMES, Feb. 20, 2000, at A26 (noting
that according to the FDA, this practice was becoming increasingly pervasive in the field

121

of gene therapy prior to the death of Jesse Gelsinger).

For example, the company Immune Response and medical researchers at the University of

California at Sa n Francisco and Ha rv a rd University have been engaged in a high-profile
dispute over publication of negative data from the Phase III trial of Remune, an anti-HIV

drug. See Eric Niiler, Company, Academics A rgue over Data, 18 NATURE BIOTECHNOLOGY
1235 ( Dec. 2000).

122

123

See Katherine S. Mangan,
Harvard Medical School Will Keep Its Co nflict-of-Interest Policies,
CHRO N. HIGH E R EDuc.,
June 9, 2000, at A36 (noting that Harvard Unive rsity even consid
ered lessening
its relatively strict standards, but then decided against that proposal). In
fact, Harvard has
joined several other re now ned medical schools in drafting joint conflicts
f
? i nterest guide lines. See Kath e rine S . Mangan, Medical Schools Draft Guidelines for Prevent
mg Conflicts of Interes t,
Cl-moN. HIGHER Eouc., Feb. 23, 2001, at A36.

.
See
M a1mow s k1. ,
.
lnstztuttonal Conflicts, supra note 4, at 72 (suggestmg that the Bush A d mm_
stra tlO
n contin ue reforms to improve
�
accountability in biomedical research). See generally
mfra Part IV.
·

·

124

·

·

·

See M rmow sk.1,
Instlf utwna/ Conflicts, supra note 4, at 54 (statmg that webs1tes sueh as
tho e of the Nati
onal Institute of Health and the Na tional Library of Medicines provide
�
onlme access
to clinica l trials, which link patien ts w i th trials).
us
Th·
. 1� tran spa
rency is attributable in part to the United States· official, FDA-managed
trial web site, nt http:/
/www.clinicaltrials.gov. For additional clinical trial web
srtes, see
supra

a

·

c�tmcal

note 99.

·

·

·
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pipeline, both patients and providers w ill more rea dily look to
clinical trials for health care options.126

Decisions by the govern

ment and other payers to cover clinical trial-related medical costs in
a reliable manner are encouraging this trend . Muddying the thresh
old between clinical trials and standard of care will have a profound
impact on professional responsibility, liability, and health c are
finance.1 27
Genetic Profiling as an Acco m p a ni m ent to Prescription

C.

Pharmaceuticals
The day when the neighborhood pharmacist routinely tailors
commercially available pharmaceuticals to account for each per
son's SNP idiosyncrasies may be decades removed. Nevertheless,
market introduction of genetic tests to make prescription drug
choices thus far is simply a glimpse into a foreseea ble fut ure. 1 28
Pharmacogenomics129 as a R&D methodology will bring forth mean
ingful pharmacogenetics130 capabilities.

In turn, these capabilities

will be utilized by the medical community to engage in individually
tailored health care delivery and prevention with significant health
outcome improvements.131 Subscriber services to inform individu
als about the latest SNP identifications that could in1pact their re
sponses to com mercially available drugs and drug interactions in an
ongoing manner are already under development.132 Such databas es

and services are presently available to members of the resear c h
126

See Malinowski, Institutional Conflicts, supra note 4, at 53-54 (describing the public percep
tion of clinical trials as creating breakthrough treatments).

127

HEALTH CARE FINANCING ADMIN., MEDICARE CovERAGE Poucv-CLINICAL TmALS, FtNA L
NATIONAL CovERAGE DECISION, at http:/ /www.hcfa.gov /coverage/8d2.htm; OEP'T OF
HEALTH & HUMAN SERVS., HEALTH CARE FINANCING ADMIN., HCFA FACT SHEET, MEDI
CARE CovERAGE RouTINE CosTs oF BENEFICIARIES IN CLINICAL TRIALS

(2000), at http: / I

www.hcfa .gov / medlearn/ ctfsl3.pdf (stating that Medicare beneficiaries would not lose
their coverage by enrolling in clinical trials in an effort to promote more innovations
through clinical trials). See also Malinowski, Institutional Conflicts, supra note 4, at 55-56
(noting that government policy is supportive of clinical care). See generally SusAN QuiNN,
HUMAN TRIALS: SciENTISTS, INVESTORS, AND PATIENTS IN

THE

QUEST FOR A CURE (Perseus

2001) (detailing a case study of the company Autoimmune which emphasized the impact
of clinical trials on patients awaiting innovative treatments).
128

Genetic profiling as an accompaniment to drug delivery is made tangible by present applications of such technology. See supra notes 64-68 and accompanying text.

1 29

See supra notes 4-5 and accompanying text.

130

See supra note 9 and accompanying text.

131 See supra note 8 and accompanying text.
132

See supra notes 69-76 and accompanying text.

MALINOWSKI

53

community, and the mission of the ongoing work of the well-fi
nanced and diligent SNP consortium is to chum out a voluminous
number of genotype-phenotype (genetic-physical characteristic)
connections. 133
The use of pharmacogenomics and pharmacogenetics by the
health care community will intensify and add new dimensions to
many standing law and policy issues. These issues include genetic
exceptionalism in both law and regulation, education of the health
care provider community, market acceptance, and patient access.
Genetic Excep tionalism

1.

Predictive genetic tests manufactured and sold to others to per
form are regulated by the FDA as medical devices.134 However, pre
dictive genetic tests performed by their manufacturers and made
available to others as a service, which are known as "homebrew
tests," escape FDA regulation and are arguably not meaningfully
regulated otherwise.13S This regulatory exceptionalism was made
all-too-clear in 1 996 and 1997 when several biotech companies en
gaged in commercializing predictive genetic tests for breast cancer
premised upon links between the disease and BRCAl and BRCA2
variations, without data to establish the clinical utility of this con133

See TH E SNP CoNSORTIUM

LTD., SINGLE

NucLEOTIDE PoLYMORPHISMS FOR BIOMEDICAL RE

SEARCH at http : / / snp.cshl.org (stating that the Consortium's mission is to research and

publicize SNPs, not that the general public will have access to this scientific information).
See also Malinowski, Snake Oil, supra note 3, at 32 (explaining that bioinformatics has used

software to create data libraries).
134

Me d ical Device Amendments of 1976, Pub. L. No. 94-295, 90 Stat. 539 (codified as
amend ed at 15 U.S.C. § 55 (1 994) and in sections of 21

U.S.C.).

See Malinowski, Snake Oil,

supra note 3, at 43-44 (recommending that Congress revise the Medical Devises Act to

enable and encourage the FDA to regulate gentic tests more broadly).

135 See Malinowski, Snake Oil, supra note 3, at 44 (explaining the only meaningful federal
oversight of homebrew testing is under the CLIA, or the Clinical Laboratory Improvement
Amendments, the scope of which is limited to regulating the proficiency /accuracy of test
ing and administrative requirements). See generally Anny Huang, FDA Regulation of Genetic
Tes ting: Institutional Reluctance and Public Guardianship, 53 Fooo & DRUG

L.J. 555,

556-57

(1998) (stating the FDA has repeatedly taken the position that it will not regulate "kits,"
even though it regulates testing services conducted at centers and laboratories). See Ge
netic Testing Under the Clinical Laboratory Improvement Amendments, 65 Fed. Reg.
25,928 (May 4, 2000) (announcing that the CLIA Committee recommended the creation of
a genetic testing specialty); CLINICAL LABORATORY IMPROVEMENT ADVISORY CoMMITTEE

( CL!AC) ,

GENERAL RECOMMENDATIONS FOR

QuALITY

ASSURANCE PROGRAM

FOR

LABORA

TORY MoLECULAR GENETIC TEsTS (Aug. 31, 1999); SEcRETARY's ADvrsoRY CoMMriTEE ON

G ENETIC TESTING (SACGT), ENHANCING THE OVERSIGHT

OF

GENETrC TESTS: RECOMMENDA

TIONS OF THE SACGT (July 2000), available at http:/ /www4.od.nihgov /oba/sacgt.htm.
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nection for women in general.136 Consequentially, patient groups,
bioethicists, and p olicy makers expressed concern that industry
would engage in premature commercializa tion of predictive genetic
tests for a multitude of multigenetic d isorders in a similar man
ner.137 The outcome was an adverse market response to these initial
tests and their manufacturers, professiona l and public criticism, and
genetic exceptionalism in state and federal law. nH Given that most
genetic tests have multiple potential uses,139 definitional ambiguity
is prevalent in this legislation. 140 Therefore, genetic exceptionalism
may prove a significant market barrier to the commercial availabil
ity of genetic profiling technologies in general and, consequently,
for utilization of pharmacogenetics to improve the delivery of
health care.141
2.

Health Care Provider Competency
The transition from fee-for-service into managed care has im

posed time and other commercial pressures on the United States
136

See Malinowski, Snake Oil, supra note 3, at 36 (stating that the absence of clinical utility can

lead to test takers unknowingly subjecting themselves to possible over-treatment, false
assurances, and discrimination by insurers and employers.
137

See id. at 35-37 (describing the marketing of tests to detect mutations in the BRCAl gene

"to predict susceptibility to the occurrences of some hereditary forms of breast cancer.'').
138

See id . at 34-37 (explaining how in the midst of a series o f federal legislative and adminis

trative initiatives, states enacted an entanglement of genetics legislation). For a concise,
organized overview of the kinds of legislation states have enacted, see William F. Mulhol
land, II & Ami S. Jaeger, Genetic Privacy and Discrimination: A Survey of State Legislation, 39

}URIMETRics J. 3 1 7, 317-26 (1999) (noting that the most prohibited actions under this legis
lation include some combination of the following: genetic testing in general; requiring or
requesting a genetic test or information; disclosing the results of a genetic test to third
parties without prior informed consent; discharging, refusing to hire, or refusing to pro
mote by employers on the basis of the results of genetic tests; affecting terms, conditions,
or disbursement of benefits based upon the results of genetic tests; refusing to consider an
application; refusing to issue or renew an existing policy; classifying information derived
from a genetic test as a preexisting condition; charging higher rates or premiums; and
discriminating charges in brokerage fees or commissions).

Exceptions are commonly

made for genetic testing in a court proceeding and genetic research. Id. at 318-19.
139

Malinowski, Snake Oil, supra note 3, at n.24 and accompanying text. Consider that a ge
netic test for over expression of Her2-neu could be used:

(1) in a woman with breast cancer

to determine whether she should consider taking certain medications for treatment, such
as Herceptin; (2) in a healthy woman with a family history of breast cancer to help assess
susceptibility to the disease and perhaps to determine whether she should take medication
as a preventive measure; or (3) perhaps by a potential mother with a family history o f
breast cancer t o screen embryos before undergoing in vitro fertilization.
140

Id. at 28-29 (highlighting that scientific definitions of "predictive genetic testing" work

relatively well in a regulatory context).

141

See generally id. at 30.
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health care con1munity. 142 Even before the spread of managed care
throughout the 1 990s, concerns were raised about the failure of most
medical school curricula to educate health care providers to deliver
care in the midst of the genetics revolution.143 The explosive ad
vancement of bio technology from the research bench into the mar
ket has validated

many of these concerns. 144

"In light of the

towering and still rising wave of informa tion, the all-knowing gen
eral practicioner is not a contemporary possibility."145
The advent of pharmacogenomics now may overwhelm the
medical community with an even more pervasive set of challenges.
Although managed care gene rail y has embraced diagnostic testing
and preventive screening, an intense deluge of additional testing as
sociated with a generation of much more expensive pharmaceuticals
would prove d ifficult to absorb. 1 46 Moreover, the market introduc
tion of a multitude of innovative pharmaceuticals accompanied by
genetic p rofiling and added decision making, a jolt in pharmaceuti
cal complexity attributable to genetic p recision, changes in long
standing disease classifications, and the commingling of clinical care
and ongoing clinical research will necessitate significant changes in
the delivery of care. Rather than making doctors and nurses assume
this entire burden, it is likely that pharmacists and non-physician
clinicians will be stepping into a n expanded role in the health care
proce ss.

142

See generally Michael J. Malinowski, Capitation, Advances in Medical Technology, and the Ad
vent of a New Era i n Medical Ethics, 22 AM. J.L. & MED. 331, 336 (1996), reprinted in TAKING
SIDES: CLASHING VIEWS ON CoNTROVERSIAL BIOETHICAL IssuEs (Carol Levine ed., 7th ed.
1997) (stating that "as a result of third-party payment of health care costs, patient consum
ers have become indifferent and insensitive to the prices of services and the costs of treat
ments, seldom considering price and cost even when they undergo elective diagnostic
tests and surgeries.").

143

Micha el

J. Malinowski & Robin J.R. Blatt, Commercialization of Genetic Testing Services: The

FDA, Market Forces, and Biological Tarot Cards, 71 TUL. L. REv. 1211, 1245-1246 (1997) (ex
plaining that the current generation of health care providers do not possess the skills to
interpret predictive genetic tests).
144

See Michael J. Malinowski, Foreword: Academic-Industry Collaborations in the Clinic,
ENER L. SYMP.

J. ii, ii-iii &

nn.

1-7

8 WID
(2001) (commenting how the market is driven by "aca

demic-industry alliances.").
145
146

Malinowski, Institutional Conflicts, supra note 4, at 54.
For an excellent treatment of the health care complexities of clinical application of ad
vances in human genetics, see generally GENETICS IN THE CLINIC: CLINICAL, ETHICAL, AND
SociAL IMPLICATIONS FOR PRIMARY CARE (Mary Mahowald et al. eds., 2001) [hereinafter
GENETICS IN THE CLINIC ] .
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Market Acceptance and Patient Access

3.

Conceivably, the public may embrace and directly pay for se
lect genetic profiling services-suc h as screening to anticipate reac
tions to major pharmaceuticals and to manage drug interactions-to
the extent necessary to make providing those services commercially
viable.147 Market acceptance also may b e realized in part through
medical community participation in life science R&D utilizing
pharmacogenomics . Major medical centers with access to samples
and patients are positioned to aggressively p ursue these opportuni
ties, and when such institutions embrace technology transfer and
commercial collaborations, their portfolios of agreements are likely
to encompass a considerble amount of clinical research. 148
Nevertheless, many in the medical community are more famil
iar with the confidentiality, privacy, and potential discrimination is
sues associated with predictive genetic testing than the technology
itself.l49 Educating the medical community about the multitude of
intricacies associated with a broad generation of drugs developed
through pharmacogenomics could prove a daunting challenge for
the life science industry. Clinical use of most predictive genetic test
ing requires considerable interpretation, and pharmacogenomics
147

notes 68-76 and accompanying text (identifying some emerging Internet services,
including genetic screening services to improve drug reactions and identify potential
problems from drug interactions).
See supra

148 See

Kowalczyk, Lucrative Licensing Deals with Drug, Biotech Firms are Raising Ethics Is
sues for Hospitals, BosToN SUNDAY GLOBE, Mar. 24, 2002, at Cl (stating "[H]ospitals have
become increasingly interested, particularly since managed care restricted their income
during the 1990s and heated competition for patients fostered a more entrepreneurial atti
tude."); see also Liz Kowalcsyk, Medical Schools Join Forces: Harvard, Others Aim to Give Drug
Firms Faster OK's on Clinical Trials, BosTON GLOBE, July 28, 2000, at Cl (reporting on an
alliance between Harvard and four other medical schools to counter the private industry's
efforts to dominate human research on new medical treatments). Medical academia is
attempting to reclaim its influence in clinical research, which has been diminished over the
last decade through the emergence and explosive growth of the global contract research
organization ("CRO") industry, led by companies such as Covance, Inc., at http: / /www.
covance.com; Parexel International Corporation, at http:/ / www.parexel.com, and Quin
tiles Transnational, at http:/ /www.quintiles.com. See Malinowski, Institutional Conflicts,
supra note 4, at note 30 and accompanying text. Nevertheless, academic institutions' em
brace of industry relationships has heightened regulatory and ethical hurdles, including
institutional conflicts. See generally id. For example, NIH concerns led to the demise of
Boston University's plans to use Framingham Study data in genomics studies. See Vicki
Brower, Framingham Heart Study Genomics Firm Stops Beating, BioTECHNOLOGY NEw
SWATCH, Jan. 15, 2001, p . 1 ., 2001 WL 8787439.

149

Uz

Malinowski, Snake Oil, supra note 3, at 35-36 (stating that many medical community insid 
ers think that "the use of predictive genetic testing with clinical utility for many common
disorders is decades removed from the present realities of managed care.").
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could add an addi tiona! dimension of complexity to drug prescrib
ing. 150 The da ngers of over-reliance on genetic profiling include
over and under dosing and false assurances. These oversights can
lead to fa ilures to cl osely monitor drug interactions or to make nec
essary dosage adjustments and drug substitutes over time. In addi
tion, the significant streamlining of clinical trials may heighten
provider

dependence

on

compiled

Phase IV

data

while

the

pharmaceuticals are being taken by patients. Even more fundamen
tal, introducing drugs genetically tailored to fit only into the eye of a
traditional disease classification may prove problematic for a medi
cal provider community accustomed to traditional disease classifica
tions, cruder pharmaceuticals, and broad off-label use.
Pharmacogenetics also will have a profound impact on reim
bursement decision-making and patient access, and set in motion a
series of market c hanges presently difficult to fully define and mea
sure.151 Just a few decades ago, prescriptions generally cost less
than $10, and a prescription charge of $100 would have caused pa
tients, health care providers, and payers to balk. However, technol
ogy has elevated costs with capabilities. 152

Pharmacogenomics

offers the potential of cost savings and human capital returns from
improved health care outcomes .153 Nevertheless, the precision re
sulting from meaningful pharmacogenomics suggests industry will
have to recoup the costs of developing these innovative drugs from
much smaller patient populations, meaning even higher drug costs
for those who take the drugs. 154 Pharmacogenomics will also intro
duce new costs, including genetic profiling, data collection and
processing, and monitoring services. Given the data collection gen150

See generally GENETICS

IN THE

CLINIC, supra note 1 46; Lee M. Silver, The Meaning of Genes

and "Genetic Rights" 40 }URIMETRics J. 9, 1 1-12 (1999) (explaining what genes are and how
they compare to others' genes).
151

See infra Part IV; see supra Part Ill. See generally Kahn, supra note 22, at 20 (identifying a
number of market variables that bear upon the market performance of the biotechnology
and pharmaceuticals sectors).

152

For example, today's technologies for cancer include Herceptin, a drug that has proven
helpful for many p atients with previously untreatable cases of breast cancer at a cost of
approximately $20,000 per patient, and a $10,000 wafer chip that delivers chemotherapy
directly into a patient's brain. See Pam Abramowitz, The Financial Impact of Genomics, THE

BoNn BuYER, Dec. 13, 2000, p . 18, 2000 WL 30670701 . See also Jurna et. al., supra note 33.
153

See generally Pincowish, supra note 50 and accompanying text.

154

See Malinowski, Institutional Conflicts, supra note 4, at n.21 (stating that the "use of
pharmacogenomics, bioinfonnatics, and related technologies will result in pharmaceuti
cals tailored to individual genetic profiles, streamlined therapeutic use, regulatory ap
proval and labeling limitations .
at 224.

.

.

. "). See also Malinowski, FDA Regulation, supra note 20,
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erated by market use, the dynamic nature of the human genome in
response to environmental stimuli, and the need to make pha rma
ceutical dosage and drug changes over time, the cost of moni toring
could prove significant.
This climate and the raging controversy over drug p r i cin g sug
gest that genetic profiling as an accompaniment to drug delivery
will have to enter the marketplace with sound evidence of clinical
utility in order to be accepted.155 Widespread medical community
acceptance is likely to depend heavily upon the safety, efficacy, and
clinical utility of the pharmaceuticals developed with pharmacoge
nomics that carry genetic profiling into the marketplace. 1 56

IV.

PROPOSALS FOR LEGISLATIVE AND REGU LATORY
REFORM
Admittedly, today's life science enabling teclmologies and

commercial investment in applying those technologies make gaug
ing tomorrow's health care a speculative endeavor even for ex
perts .157 Nevertheless, recent history is telling: biotechnology and
genetic medicine have influenced the d elivery of care in jolting
ways over the last decade.158 Therefore, in the context of
pharmacogenomics, pragmatism mandates not assuming the luxury
of time to resolve major law, business, and health care challenges
associated with this technology. This article has identified many of
155

Malinowski, Snake Oil, supra note 3, at 4 1 . See also Milt Freudenheim & Melody Petersen,
The Drug-Price Express Runs into a Wall, N.Y. TrMEs, Dec. 23, 200 1 , at 1 (reporting that
market resistance to new drugs in the absence of significant clinical utility offsets price
increases) .

156

P resumably, the FDA will require precision labeling for drugs developed with heavy utili
zation of genetic profiling, and the FDA may even require genetic profiling as

a

pre-condi

tion for approved market use. For a technical treatment of the FDA's review of new drugs
and approval process, see MAUNOWSKI, BIOTECHNOLOGY, supra note 88, at ch. 1 1 .
157 S ee Kahn, supra note 22, a t 20; Freudenheim & Petersen, Drug-Price Express, supra note 155,
at 1 (stating that the rise in health insurance premiums and an economic downturn has led

to an unstable drug market). Cf Malinowski, Snake Oil, supra note 3, at 47 (charting how
current enabling techniques allow industry players to develop new research possibilities).
158

In

1 995, there

were only eight biotech-derived pharmaceuticals on the market. Toda y,

there are over 100. For identification of the present drug development pipeline, see http:/
/www.phrma.org (site of the Pharmaceutical Researchers and Manufacturers of America
(PhRMA), the world 's leading pharmaceutical trade organization); http:/ /www.bio.org
(site of the Biotechnology Industry Organization (BIO), the w orld s leading biotechnology
'

industry trade organization). For identification of the biotech drugs on the market in 1995,
see Michael

J.

Malinowski & Maureen A. O'Rourke, A False Start? The Impact of Federal

Policy on the Genotechnology Industry, 13 YALE

J.

ON REG. 163, n.

1 (1996).
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these cha l l en ges a n d en1 p hasizcd tha t novv is the time to address

them.

A prc rn i se i n1pl ied throughout this article is that those en
ga ged i n s h a pi ng hea l th law, hea l th p o l icy, and bioethics must re
search a n d a d d ress the uti l i zation of innovative technologies in the
drug devel opn1ent pipel ine and the transition of resulting technolo

gies into the delivery of health care in a diligent manner. 1 59 Argua
bly, i n m a ny a re a s where law and science overlap, the long-standing
divide between technology and responsive, fact-based, otherwise
pragmatic, and i n telJ ectually thoughtful law and policy has wid
ened into an abyss over the last decade or so.160 Given the quicken
ing

pace

of

advances

in

contemporary

life

science

through

bioinformatics and other enabling technologies,161 the divide be
tween law and life science continues to widen in several now press
ing areas and with increasingly dire health, economic, policy, and
ethical consequences, thereby raising more complicated regulatory
chal lenges. 162 A generation of unprecedented, often breakthrough,
life science is now reaching delivery o f care and entering a United
States health care finance system that has been critiqued for decades
for failing to guaranty a minimum standard of care for the U.S. pop
ulation. 1 63 The number of uninsured and insufficiently insured has
risen over the years to reach more than forty million Americans, and
those ranks continue to expand and include more working Ameri
cans. 164 Moreover, accurately gauging the entry of specific scientific
capabilities into health care application, especially under the expan
sive shadow cast by the unpredictability of advances i n enabling
159

See Malinowski, Snake Oil, supra note 3, at 39-41 (discussing "Shared Responsibility for
W idening the Gap.").

1 60

See id. at 39 (commenting that the Ethical, Legal, and Social Implications (ELSI) program of
the HGP has overlooked the "systemic introduction of predictive genetic testing into
health care'').

161

See supra

Part

I

("Traditional

Pharmaceuticals

and

the Changing

Pharmaceutical

Economy").
162

See Michael J. Malinowski, Biotechnologt; in the USA: Responsive Regulation in the Life Science
Industry,

163

2 INT'L J. BIOTECHNOLOGY 16 (2000).

See generally Richard D. Lamm, Universal Health Care Coverage: A Two-Front War,
GAL

MEo.

22 J. LE

225, 225-27 (June 2001) (stating that 1 6% of the United States popula tion has no

health insurance, and that this uninsured population tends to be more sick o n average
than those people with health insurance).
164

See Arthur Jones, Stretched to the Limit, NAT'L CArn. REP., Feb.

22, 2002, at 3, 2002 WL

10828411 (explaining that there are approximately forty million uninsured /insufficiently
insured citizens in the United States and that many of those joining the ranks of the unin
sured are working Americans).
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technologies, l6S is a Herculean task.166 The present state of some ar
eas of relevant law and scholarship suggest that the legal profession
has yet to engage in a meaningful, ongoing dialogue with those
pushing out the forefronts of life science R&D and directly engaged
in health care innovation.l67

165

See Malinowski, Snake Oil, supra note 3, at

26 (describing how enabling technologies have

had an explosive impact on biotechnology R&D-perhaps mostly to the surprise of the
health care community).
166

See s upra note

167

Patent law provides a pressing example, for intellectual p roperty policy innately presumes

22 and accompanying text.

insight about and sensitively towards markets, economic reality, and the actual practices
of technology innovators.
CALS

AND

Cf

BIOTECHNOLOGY:

PHILIP W. GRUBB, PATENTS FOR CHEMICALS, PHARMACEUTI

FUNDAMENTALS OF

GLOBAL

LAW,

PRACTICE

AND

STRATEGY

(1999) [hereinafter "Patents for Chemicals" ] (noting in the p reface that "in the previous edi
tion [of this treatise] a number of predictions were made, most of which turned out to be
completely incorrect."). Arguably, the U.S. patent regime did not anticipate the jolting
advances in the state of the art introduced by fields such as biotechnology, genomics, and
bioinformatics over the last several years and, in hindsight, patent criteria may have been
interpreted too broadly throughout the

1990s. The USPTO responded in January 2001 by

issuing revised standards for written description and utility in genetics. See Utility Exami
nation Guidelines,

66 Fed. Reg. 1092, 1092-1099 Oan. 5, 2001) (setting forth specific stan
dards); Guidelines for Examination of Patent Applications Under .the 35 U.S.C. § 1 12, Pl,
"Written Description" Requirement, 66 Fed. Reg. 1099 (2001). Ideally, as concern about
over patenting in biotechnology became a pressing topic in the early 1990s, law academia
should have responded by undertaking pragmatic field work in the life science sectors,
demonstrating appreciation for ''real world" implications, and then setting forth insightful,
sector-sensitive proposals to modify application of traditional patent criteria and practices
while remaining faithful to these core criteria. Certainly, some of this work was done. See,
e.g., James Donahue, Note, Patenting of Human DNA Seq ue11ces-Implications for Prenatal

J.

267, 282 (1997-1998). Nevertheless, even after for
mer President Clinton and Prime Minister Tony Blair made statements on March 14, 2000
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critical of biotechnology patenting that caused the biotechnology market sector to drop b y

$100 billion over the next 24 hours, some l a w academics have continued to fail t o distin
guish the information technology sector from the life science sector with meaningful sensi
tivity reflective of the obvious scientific, economic, and other "real world" differences. See
Andrew Pollack, Protecting A Favorable

Image:

Biotechnology Col!cer1zs itt Quandary Over

Drug Giants, N.Y. TIMES, Apr. 4, 2000, at Cl. See also Mal inowski, Snake Oil, supra note 3, at
n.22. For example, some have proposed transplanting cornerstone doctrine in copyright
and trademark such as "fair use," a doctrine proven workable for the information technol
ogy and publishing sectors, into the body of patent jurisprudence.
O' Rourke, Toward

a

Doctrine of Fair Use in Patent Law,

See Maureen A.

100 CoLUM. L. REv. 1 1 77, 1236-1 237

(2000). While expansion of mechanisms already present in the patenting regime such a s
the reexamination procedure may prove desirable and even critical for the advancement o f
life science, analysis should embody understanding o f and appreciation for the technical,
pragmatic differences between life science R&D and other sectors that rely much more
heavily on copyright and trademark protection. The extraordinary rate of failure, cost,
time, and other risks-such as regulatory uncertainty and market unpredictability-asso
ciated with life science R&D readily distinguish the sector. See

GRuBe,

sup ra

note

167, at

225-226 (highlighting the perspective of a European patent attorney with decades of prac
tice experience in multiple, technology-driven sectors). As demonstrated in March 2000
and recognized by the National Institutes of Hea l th in its August 2001 report, significantly
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One might argue, therefore, that there is a moral imperative in
addition to a professional obligation to bridge law and policy with
meaningful fieldwork (meaning laborious fact gathering) in both life
science R&D and health care delivery, and to thereby proactively
address foreseeable health law, policy, and bioethics challenges in a
pragmatic manner. Given the life and death ramifications of health
law and policy, in addition to academic theory and intellectual ca
pabilities, those in the field must and a pproach issues with a "criti
cal mass" of practical knowledge in: (a) regulation and legislation
along the entire R&D continuum from the laboratory bench to the
health care marketplace,

(b) the economic and other realities of life

science R&D, (c) health care delivery, and (d) the health care
marketpla ce .
In recent scholarship, this author and others have proposed
regulatory /law and institutional reforms to address many of the
challenges that will be exacerbated by the advent of pharmacoge
nomics, including access to human biological materials, protection
of human subjects, conflicts of interest, and commingling of clinical
c are and clinical research.168 The reforms proposed by this author
include revisiting the present state legislative scheme encompassing
predictive genetic testing, 169 introducing reliable federal information
management systems for both human subject protection and tech
nology transfer,170 coupling federal oversight capabilities with en
forcement (such as compliance audits in both human subject
protection and technology transfer),171 and bridging grant compli
ance and technology transfer within health science institutions.172
weakening the patent regime would have dire consequences on the behavior of those who
invest their careers-whether based in academia or industry-in pharmaceuticals, and
presumably even more dire consequences for the patients and their families and friends
who await their commercial development and availability. See generally DEr'T HEALTH &
HuMAN SERvs., NAT'L INsT. oF HEALTH, NIH RESPONSE ro THE CoNFEHENCE REPORT RE
QUEST FOR A PLAN TO ENSURE TAXPAYERS' INTERESTS ARE PJ{OTECTED

http : / /www.nih.gov /news/070101wyden.htm.

But see Arti K.

(July 200 1 ), available at
Rai,

Tire Information

Revolution Reaclzes Pharmaceu ticals: Balmzcing In n ova t io n I11centives, Cost, & Access in tlze Post
Genomics Era, 2001 U. ILL.

L. REv. 173, 1 78-80 (2001) (proposing a curtailment of patent

rights premised on cost savings attributable to use of pharmacogenomics).
168

J. Malinowski, Symposium, Conflicts of Interest in Clinical Research:
Legal and Ethical Issues, 8 WIDENER L. SYMP. J. 47 (2001); Malinowski, Snake Oil, supra note

See generally Michael

3, at 41-46 (explaining his thesis in ''A Proposal For Regulatory Reform'').
169
170

See generally Malinowski, Snake Oil, supra note 3, at 41.
See generally Malinowski, Institutional Coriflicts, supra note 4, at 69-73 (suggesting new

changes in "Proposals for Reform").
171

ld.
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This article has framed a series of additional questions which
culminate in the following: Given opportunities to introduce more
meaningful preventive care and to improve health care outcomes
through commercialization of pharmacogenomics, to what extent
should the legal and health care environments be made more wel
coming to this technology to accelerate its widespread use? Even if
this technology introduces significant short-term costs, should these
costs be absorbed by a health care system already failing to cover
millions of citizens? If yes, then at what price? Consider tha t by
shattering traditional disease classifications, 173 raising the costs of
pharmaceuticals,l74 and introducing a genetic profiling element to
drug prescribing and, more generally, to the delivery of care,175
pharmacogenomics is likely to push United States health care into
an era of much more pervasive and extreme tiering of coverage and
access. Also, given that under such circumstances many genetic
profiling services may be sought and purchased directly by the p ub
lic,176 it is time to consider introducing w orkable yet meaningful
safeguards for direct communication between the public and com
mercial providers of genetic profiling services.177
The medical, life science, and legal communities must work
through the entanglement of variables encompassed by these ques
tions to come up with algorithms that work on a collective level,
especially since the United States continues to lack reliable federal
regulatory oversight of predictive genetic testing services.178 Crite
ria must be developed to guide health care providers, the public,
and payers to make decisions about clinical utility and responsible
medical use of genetic profiling technologies.

For example, al

though meaningful genetic profiling cap abilities presumably will b e
developed and introduced in a spora dic manner over the next few
decades, genetic profiling ultimately should prove as pervasive as

1 73

See Malinowski, Institutional Conflicts, supra note 4, at n.21; see also Malinowski, FDA Reg u 
lation , supra note 20, at 224.

174

See Malinowski, Institutional Conflicts, supra note 4, at n.21 (explaining that cost hikes can
impede industry innovation).

175 See

generally Malinowski, Snake Oil, supra note 3, at 31 (commenting that individualized

medical treatment is a notion "decades removed").
176
177

See supra note 132 and accompanying text.
Melody Petersen, TV Ads Spur a Rise in Prescription Drug Sales, N.Y. TIMES, Mar. 8, 2002, at
C13. Cf Malinowski, Snake Oil, supra note 3, at 34;

1 78

For a thoughtful discussion of the complexities of using genetics in the clinic, see generally
GENETICS IN THE CLlNIC, supra note 145.
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genetics in human health . 1 79 During the interim, law should be used
to ensure that the basic tenets of health insurance, meaning p ooling
and disbursement of risks across the population, are adhered to.
Sight must also not be lost of the fact that prolifera tion of under
standing about human genetics, widespread genetic testing, and the
resulting flow of information should make genetics
purposes

of

health

insurance

payers.

Heavy

a

"wash" for the
utilization

of

pharmacogenomics in drug development, coupled with proactive
regulatory, other law, and health policy reforms identified through
out this article, should quicken our transition through the awkward
period of introduction and into the future of health care.

CoNcLusioN
The

complexities

associated

with

pharmacogenomics are extraordinary .

commercialization

of

This article has identified

and discussed many of these complexities, including those associ
ated with the changing pharmaceutical economy, trends in pharma
ceutical R&D, and implications for the delivery of health care 1nd
the roles of p a tients, research subjects, and providers.
Nevertheless, pharmacogenomics introduces tremendous op
portunities to improve health care, realize some immediate cost sav
ings (for example, reducing the incidents of adverse reactions to
pharmaceuticals), and increase human health and capital.

There

fore, the legal, medical, and life science communities must rise to
the challenge of working through the complexities associated with
pharmacogenomics rather than continuing to assume the luxury of
time or simply d amning the endeavor and looking away.
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See Malinowski, Snake Oil, supra note
netic Exceptionalism'').

3, at 33-41 (considering "The Consequences of Ge

